You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Methoxyluteolin
Methoxyluteolin inhibits release of pro-inflammatory mediators from mast cells and decreases gene expression and release of TNF, VEGF and IL-8/CXCL8. The product also significantly inhibits IL-33 stimulated expression and release of CCL5 and CCL2. Methoxyluteolin pretreatment of LAD2 mast cells decreases gene expression of TNF, CXCL8 and VEGF in response to neurotensin or substance P via mTOR activation.
Technical Data for Methoxyluteolin
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Methoxyluteolin
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Methoxyluteolin
The following data is based on the product molecular weight 342.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||14.6 mL||73.02 mL||146.05 mL|
|1 mM||2.92 mL||14.6 mL||29.21 mL|
|2 mM||1.46 mL||7.3 mL||14.6 mL|
|10 mM||0.29 mL||1.46 mL||2.92 mL|
References for Methoxyluteolin
References are publications that support the biological activity of the product.
Abubakr Bawazeer and Theoharides (2019) IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Eur.J.Pharmacol. 865 PMID: 31669588
Weng et al (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J.Allergy Clin.Immunol. 135 1044 PMID: 25498791
Patel and Theoharides (2017) Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J.Pharmacol.Exp.Ther. 361 462 PMID: 28404689
Taracanova et al (2018) Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc.Nat.Acad.Sci. USA 115 9381 PMID: 30232261
If you know of a relevant reference for Methoxyluteolin, please let us know.
View Related Products by Product Action
Keywords: Methoxyluteolin, Methoxyluteolin supplier, methoxyluteolin, mast, cells, inhibitors, inhibits, cytokines, Cytokines, 7320, Tocris Bioscience
Citations for Methoxyluteolin
Citations are publications that use Tocris products.
Currently there are no citations for Methoxyluteolin. Do you know of a great paper that uses Methoxyluteolin from Tocris? Please let us know.
Reviews for Methoxyluteolin
There are currently no reviews for this product. Be the first to review Methoxyluteolin and earn rewards!
Have you used Methoxyluteolin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.